BRL 28500 (Clavulanic acid-Ticarcillin) の基礎的・臨床的検討 STUDIES ON THE ANTIMICROBIAL ACTIVITIES AND CLINICAL EFFECTS OF BRL 28500 (CLAVULANIC ACID-TICARCILLIN)

Access this Article

Author(s)

Abstract

Clavulanic acid (CVA) とTicarcillin (TIPC) の合剤であるBRL 28500について抗菌力, 臨床効果の検討を行った。<BR>抗菌力: <I>S. aureus, S. epidermidis, E. faecalis, α-Streptococcus, E. coli, S. typhi</I> および他の<I>Salmonella</I> spp., <I>Shigella</I> spp., K.pneumoniae, K. oxytoca, E. aerogenes, S. marcescens, C. freundii, P. vulgaris, P. mirabilis, P. inconstans, P. rettgeri, M. morganii, P. aeruginosa, P. cepacia, X. maltophilia, A. hydrophila, V. parahaemolyticus, V. alginolyticus, A. calcoaceticus, <I>Flavobacterium</I> spp., <I>H. influenzae, H. parainfluenzae</I> 各菌種についてBRL 28500, TIPC, Ampicillin (ABPC), Piperacillin (PIPC) およびSulbenicillin (SBPC) のMICを測定し, 比較検討した。グラム陽性菌に対してはABPCが最もすぐれた抗菌力を示し, BRL 28500とTIPCの抗菌力に差はみられなかった。<I>K. pneumoniae, K. oxytoca, P. vulgaris, K. maltophilia</I> に対しては, BRL 28500の抗菌力はTIPCに比して明らかにすくれ, CVAの効果が確認された。<I>S. marcescens, P. mirabilis, P. rettgeri</I> に対してもCVAの効果がみられた。その他のグラム陰性菌に対してはBRL 28500とTIPCの間には抗菌力に差はみられなかった。<BR>肺炎8例 (マイコプラスマ肺炎4例, 急性肺炎4例) に投与し, 著効1例, 有効2例, 効果不明5例の結果を得た。原因菌が想定出来たのは<I>S. aureus, S. pneumoniae</I>それぞれ1例ずつであったが, 共に除菌された。<BR>副作用としては1例でGPT値の軽度上昇がみられた。

The antimicrobial activities of BRL 28500, mixture of ticarcillin (TIPC) and clavulanic acid (CVA), were examined against the stock strains of clinical isolate using the plate dilution method with the inoculum size of 10<SUP>6</SUP> cells/ml. And the activities of BRL 28500 were compared with that of TIPC, ampicillin (ABPC), piperacillin (PIPC) and sulbenicillin (SBPC).<BR>Against Gram positive cocci, such as <I>S. aureus, S. epidermidis, E. faecalis</I> and <I>α-Streptococcus, </I> ABPC showed the strongest antimicrobial activity, and the activities of BRL 28500 were almost the same as that of TIPC.<BR>Antimicrobial activities of BRL 28500 were obviously superior to that of TIPC against <I>K. pneumoniae, K. oxytoca, P.vulgaris</I> and <I> X. maltophilia.</I> Against <I>S. marcescens, P. mirabilis</I> and <I>P. rettgeri</I> also observed additive effect of CVA to TIPC. Against the remaining Gram negative bacilli, such as <I>E. coli, Salmonella</I> spp., <I>Shigella</I> spp., <I>E. aerogenes, C. freundii, P. mirabilis, P. inconstans, M. morganli, P. aeruginosa, P. cepacia, A. hydrophila, V. parahaemolyticus, V. alginolyticus, A. calcoaceticus, Flavobacterium</I> spp., <I>H. influenzae</I> and <I>H. parainfluenzac, </I> the activities of BRL 28500 were about the same as TIPC.<BR>Clinical evaluation was arried out 8 cases of respiratory tract infection, containing 4 cases of mycoplasma prieumoilia. Excellent responses in one case, good in 2 cases and unevaluable in 5 cases were observed. <I>S. aureus</I> and <I>S. pneumoniae</I> was isolated in each one case as the causative agent, and the cocci were eradicated after the treatment with RL 28500.<BR>Laboratory abnormality was observed in one case consisting of slight elevation of serum GPT value.

Journal

  • CHEMOTHERAPY

    CHEMOTHERAPY 34(Supplement4), 648-657, 1986

    Japanese Society of Chemotherapy

Codes

Page Top